My Blue Dots

PALO ALTO, Calif.–(BUSINESS WIRE)–Ronald McDonald House Charities Bay Area (RMHC Bay Area) is thrilled to announce the appointment of six dynamic new members to its Board of Directors. Each brings a unique mix of experience, passion, and commitment to the organization’s mission and programs that remove barriers, strengthen families and promote healing. The new board members, joining RMHC Bay Area, include: Chase Lyman, co-chief real estate officer at the Sobrato Organization and a long-time s

IRVINE, Calif.–(BUSINESS WIRE)–Lindora, a leader in medically guided weight loss and metabolic health solutions, is excited to announce complimentary body composition assessments have begun this month in celebration of National Staying Healthy Month to kick off 2025. These free consultations will continue through the end of the month across Lindora’s 30 California locations. Lindora’s body composition assessments provide information ranging from current weight, BMI, body fat percentage, muscl

JERSEY CITY, N.J.–(BUSINESS WIRE)–Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health company, to develop innovative treatments for patients with age-related macular degeneration (AMD). This relationship, initiated in 2024, represents a major step forward by bringing together Bausch + Lomb’s extensive expertise in ophthalmology with Character Bio’s integrated patient data platform a

BOSTON & SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and

CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 5, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President &

BEIJING & ALAMEDA, Calif. & TAIPEI–(BUSINESS WIRE)–(美国商业资讯)– 百奥赛图（HKEX：02315）与育世博（6976.TT）今日正式宣布达成战略合作，启动双特异性抗体双药物偶联物（BsAD2C）的共同开发计划。该合作计划旨在针对肿瘤治疗中最具挑战性的问题—肿瘤异质性与药物抗药性，提供创新性的解决方案。 百奥赛图总裁兼首席执行官沈月雷博士表示：“我们非常高兴能够与在点击化学技术领域拥有深厚专业知识的育世博公司展开合作。此次合作将我们的RenLite®双特异性抗体与育世博的选择性抗体双药物技术相结合，我们期待共同探索高效双特异性抗体双药物偶联物（BsAD2C）的治疗潜力。” 育世博共同创办人兼首席执行官肖世嘉博士表示：“百奥赛图拥有卓越的双特异性抗体技术以及高度协作的团队，是推进我们AD2C平台的理想合作伙伴。本次合作重新定义了ADC设计的可能性，并有望为急需新疗法的患者带来突破性治疗选择。” 这次合作将百奥赛图的RenLite®平台与育世博的抗体双药物连接（AD2C）技术结合，通过双效载药的创新方法，针对多重治疗和疾病路径进行

SALT LAKE CITY–(BUSINESS WIRE)–Varex Imaging Corporation (Nasdaq: VREX) announced today that management is scheduled to participate in the following upcoming investor conferences. BTIG at Snowbird: The 12th Annual MedTech, Digital Health, LS&D Tools Conference in Salt Lake City, UT – Wednesday, February 12, 2025 (1×1 meetings only) B. Riley Securities Precision Oncology & Radiopharma Conference – Friday, February 28, 2025 in New York, NY (1×1 meetings only) About Varex Varex Imaging C

CAMBRIDGE, Mass.–(BUSINESS WIRE)–MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced the in-licensing of a next-generation selective PARP1 (poly ADP-ribose polymerase) inhibitor, now known as MOMA-989. The company also provided an update on the clinical progress of Polθ inhibitor MOMA-313 and outlined the clinical path for Werner inhibitor MOMA-341. “The addition of this selective PARP1 inhibitor